Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Champions Oncology (CSBR) Other Operating Expenses (2016 - 2026)

Champions Oncology has reported Other Operating Expenses over the past 17 years, most recently at $11.6 million for Q1 2026.

  • For Q1 2026, Other Operating Expenses rose 37.59% year-over-year to $11.6 million; the TTM value through Jan 2026 reached $40.6 million, up 13.34%, while the annual FY2025 figure was $36.2 million, 1.82% down from the prior year.
  • Other Operating Expenses for Q1 2026 was $11.6 million at Champions Oncology, up from $9.3 million in the prior quarter.
  • Over five years, Other Operating Expenses peaked at $11.6 million in Q1 2026 and troughed at $7.8 million in Q2 2022.
  • A 5-year average of $9.2 million and a median of $9.3 million in 2025 define the central range for Other Operating Expenses.
  • Biggest five-year swings in Other Operating Expenses: decreased 12.68% in 2025 and later surged 37.59% in 2026.
  • Year by year, Other Operating Expenses stood at $9.1 million in 2022, then dropped by 7.98% to $8.4 million in 2023, then increased by 9.1% to $9.2 million in 2024, then increased by 0.88% to $9.3 million in 2025, then grew by 25.15% to $11.6 million in 2026.
  • Business Quant data shows Other Operating Expenses for CSBR at $11.6 million in Q1 2026, $9.3 million in Q4 2025, and $9.9 million in Q3 2025.